QUIGLEY CORPORATION (QGLY)

[mjm2005]

Press Release Source: The Quigley Corporation

Quigley Enlists Leading Radiation Oncology Researcher to Assist in the Development Plan for Radiological Testing of QR-336 Compound
Monday April 3, 7:30 am ET
Company Plans to Develop Successful Animal Model to Comply with FDA Animal Efficacy Rules for Radio-Protective Agents

DOYLESTOWN, Pa., April 3 /PRNewswire-FirstCall/ -- Quigley Pharma, a wholly owned subsidiary of The Quigley Corporation (Nasdaq: QGLY - News), announced today that it has signed an agreement with Dr. William H. McBride, the Vice Chair of Research, Department of Oncology at UCLA to help develop an appropriate animal model radio protective research program for QR-336 to comply with New Food and Drug Administration animal efficacy rules for radio- protective pharmacological compounds.

"We are very happy to have a distinguished expert in Dr. McBride involved with the protocol development process," said Dr. Richard Rosenbloom, COO and Executive Vice President. "His experience developing radiological clinical trials makes him uniquely qualified to design the proper studies to test the effectiveness of this compound."

The QR-336 compound has demonstrated encouraging results in a preliminary non-GLP animal study against ionizing radiation. A further in-vivo study involving pre-treating mice with QR-336, followed by lethally irradiating the treated and untreated groups has shown a four-fold increase (80% survival rate) in mice surviving the otherwise lethal dose of radiation as compared to the non-treated group. Results also show that bone marrow extracted from animals that were previously treated with QR-336 and irradiated, could protect another set of irradiated animals whereas bone marrow also extracted from untreated, irradiated mice could not protect lethally irradiated animals.

QR-336 is being investigated to potentially reduce the effects of ionizing radiation, which could affect cancer patients undergoing radiation therapy, nuclear-terrorism (i.e. dirty bomb), the nuclear industry, healthcare professionals as well as commercial airline flight crews. Ionizing radiation has been linked to Leukemia and other pathology. The development of a naturally derived non-toxic drug could potentially offer some protection against these effects

About William McBride, Ph.D.

Dr. McBride is the Vice Chair of Research, at the Department of Radiation Oncology as well as the principal investigator of the UCLA Center for Biological Radioprotectors, which serves as an NIAID - biodefense: Center for Medical Counter Measures Against Radiation. Dr. McBride's far-reaching industry expertise includes participation in a series of meetings under NIH, DHHS, FDA and other government offices designed to determine what animal models make sense for radiation. He was one of the co-authors of the meeting report "Animal Models for Radiation Injury, Protection and Therapy."

Editorial Boards
Cancer Immunology Immunotherapy, 1982-1992
Immunology, 1982-1993
Radiation Research, 1992-1996
Cancer Gene Therapy, 1995-Present
International Journal Radiation Oncology Biology Physics, 1995-197, 1998-
2000, 2001, 2003, 2005
Occasional referee for papers to: Biotechniques, Blood, Cancer, Cancer
Gene Therapy, Cancer Research, Clinical Cancer Research, Clinical
Experimental Immunology, European Journal of Cancer, International
Journal of Cancer, International Journal Radiation, Oncology Biology
Physics, Journal of Cell Biology, Journal of Cellular Immunology, Journal
of Clinical Oncology Radiotherapy, Journal of Immunology, Journal of
Immunotherapy, Journal of Laboratory Immunology, Metastasis Journal,
Molecular Carcinogenesis, Nature, Radiation Oncology Investigations,
Radiation Research, Radiotherapy and Oncology.

Committee Work
International Congress of Radiation Research
Program committee, 13th International Congress of Radiation Research,
2005-2007
Radiation Research Society
President-Elect, 2005
American Society for Therapeutic Radiology and Oncology
Research Council (Vice-Chair), 2003-2005

Grant Assessor and Reviewer (National/International)
National Institutes for Health/National Cancer Institute
Pathology Study Group, 1980
Cancer Research Manpower Review Committee, 1988-1993, 1995, 1996, 2002
T32 and RO3 Grants Study Section, ad hoc, Washington D.C., 1997
Radiation Study Section
Ad hoc, Washington D.C., 1992, 1996
Permanent member 1997-2001
Chair, 2000-2001
Bioshield NIAID Grant Review Committee (Chair), 2004
NCI Program Project Parent Committee D,7 2005-2006, 2008
Department of Energy
Department of Defense
American Board of Radiology
American Society for Therapeutic Radiology and Oncology
American Institute of Biological Sciences/US Army Medical Research and
Material Command - Panel D Two: Anti-Radiation Drug
Development/Tungsten Grant Review Committee, 2005

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND for human study or take any other action to allow the aforementioned compound to be marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

(Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE® family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE® lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

All media inquiries for Quigley Pharma and Dr. McBride should be directed to:

CONTACT: Media Investor Relations
Karen Pineman Carl Hymans
G.S. Schwartz & Co. G.S. Schwartz & Co.
212.725.4500 212.725.4500
[e-mail] [e-mail]


Source: The Quigley Corporation

http://biz.yahoo.com/prnews/060403/nym023.html?.v=46&printer=1